Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study.

Baltazar GomezMancillaMatthew N MeriggioliAngela GengeRonenn RoubenoffPascal EspiéCyrielle DupuyNicole HartmannNicole PezousArvind KinhikarMia TichyAnnie DionneJohn VissingHenning AndersenBenedikt SchoserAndreas MeiselBerit JordanFarida DevlikamovaIrina PoverennovaFatima StuchevskayaThy-Sheng LinJames S RushPeter Gergely

Published in: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2023)

Iscalimab showed favorable safety and improvements compared with placebo in non-thymectomized patients with moderate-to-severe MG. It did not show any protective effect in patients with moderate-to-severe MG.

Keyphrases

monoclonal antibody
high intensity
early onset
myasthenia gravis
drug induced
open label